Home Tags IMMU-130

Tag: IMMU-130

Phase II Results with Labetuzumab Govitecan (IMMU-130) Demonstrate Promissing Efficacy as...

Labetuzumab govitecan (IMMU-130), and investigational antibody-drug conjugate being developed by Immunogen, the second agent from the company's first-in-class antibody-drug conjugate (ADC) program, produced encouraging...

United States Patent and Trademark Office Awards New Patents to Immunomedics

Earlier this month the United States Patent and Trademark Office awarded U.S. Patent 9,458,242 to Immunomedics for additional claims under the patent family “Dosages of...

New Data on Novel ADC For Solid Cancer Presented at Joint...

Clinical data on IMMU-132, an anti-TROP-2-SN-38 Anitbody-drug Conjugate currently being evaluated in patients with solid tumors, presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and...

FEATURED RESOURCES